INS and metabolic syndrome: On the other hand, a review of literature data performed in 2004 (MacLean et al., 2004), including diabetes as well as metabolic syndrome patients, suggested the inability of ω-3 PUFAs to have a direct outcome on fasting plasma glucose, insulin level, glycosylated hemoglobin (HbA1C) levels or insulin sensitivity.